Zero ad trackers.We never sell your data.
Home/Rare Diseases/Desmoid Tumors

Connective Tissue & Musculoskeletal

Desmoid Tumors Clinical Trials and Treatments

Also called Desmoid Tumor, Aggressive Fibromatosis, Desmoid-Type Fibromatosis, Desmoid Fibromatosis, Desmoid

A desmoid tumor grows from fibroblasts, the cells that make the body's connective tissue. NORD describes it as a benign tumor because it does not spread to other parts of the body, but it can grow into the tissue around it, which is why it is also called aggressive fibromatosis.

In plain words, a desmoid tumor is a rare growth of the tough tissue that holds muscles and organs in place. It does not spread to other organs, but it can push into nearby tissue, cause pain and come back after surgery.

Get an email when new Desmoid Tumors trials open or the FDA decides. Get alerts

Desmoid Tumors

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 10 studies with no phase, like observational studies, and 1 phase 4 study following medicines after approval.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines1

Ogsiveo

Desmoid Tumors has 1 FDA-approved medicine, 17 open or active clinical trials (16 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

More about Desmoid Tumors

The National Cancer Institute says desmoid tumors are most often found in the abdomen, shoulders, upper arms and thighs, and that most do not shorten life, though they can be painful and hard to get rid of.

Keep reading about Desmoid Tumors

Most desmoid tumors that are not inherited carry a change in the CTNNB1 gene, which NORD says is found in up to 85% of them. Changes in the APC gene cause the desmoid tumors seen with familial adenomatous polyposis and about 10-15% of other cases. Both changes lead to a buildup of a protein called beta-catenin, which pushes cells to keep growing. A biopsy confirms the diagnosis.

Because some desmoid tumors stay stable or shrink on their own, NORD and the National Cancer Institute both describe careful watching with regular MRI or CT scans as a common first step. When a tumor grows or causes symptoms, options include medicines, cryoablation, surgery and radiation; NORD reports that the tumor returns in 20-30% of people after surgery. In November 2023 the FDA approved Ogsiveo (nirogacestat), the first medicine approved for desmoid tumors, for adults whose tumors are progressing and need systemic treatment.

What are the symptoms of Desmoid Tumors?

These are common symptoms of Desmoid Tumors, and how strong they are varies from person to person.

  • A lump or swelling, often painless at first
  • Pain when the tumor presses on nerves or muscles
  • Trouble moving a limb or limping
  • Belly pain or bowel blockage from tumors in the abdomen
  • Poor sleep from pain
  • No symptoms at all in some people

Who gets Desmoid Tumors?

NORD says desmoid tumors are most common between ages 10 and 40 and about twice as common in women as in men, while children of both sexes are affected equally. The National Cancer Institute puts most cases between ages 15 and 60. They are more common in people with familial adenomatous polyposis (FAP), an inherited condition: NORD reports that 3.5-32% of people with FAP develop them.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Desmoid Tumors?

There is currently 1 FDA-approved medication for Desmoid Tumors.

nirogacestat
SpringWorks Therapeutics (part of Merck KGaA, Darmstadt, Germany)
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Desmoid Tumors treatment

Charity funds and drugmaker programs for Desmoid Tumors, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on November 2, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Desmoid Tumors, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

How Desmoid Tumors is diagnosed

Most desmoid tumors are not inherited and carry a CTNNB1 change found only in the tumor. The National Cancer Institute says about 5-10% run in families, mainly with familial adenomatous polyposis (FAP), which is caused by an inherited APC variant and passed on in an autosomal dominant pattern (NORD).

Trusted Desmoid Tumors resources

Reputable organizations and medical references for learning more about Desmoid Tumors, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Desmoid Tumors

Use this Desmoid Tumors clinical trial finder to see the 16 studies recruiting patients and 1 opening soon in the United States and worldwide, with eligibility criteria in plain English. Of these, 11 test a treatment and 6 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

17 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 2Recently updatedNCT07541430

A Study in Adults With Desmoid Tumors

Intervention: ES014, ES014

Sponsor: Elpiscience (Suzhou) Biopharma, Ltd.

This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics (PD) of ES014 in adult desmoid tumor patients.

Ages 18 Years+1 location
Started Apr 2026Updated 1 week agoEst. Jan 2028 (~1y 2m)
RecruitingTreatment trialPhase 4Recently updatedNCT07176689

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Intervention: Nirogacestat

Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

This study is being conducted to study how nirogacestat may affect the ovarian function of adult premenopausal women with progressing desmoid tumors/aggressive fibromatosis.

Ages 18 Years to 40 Years23 locations
Started Sep 2025Updated 2 weeks agoEst. Feb 2031 (~4y 3m)
RecruitingTreatment trialPhase 1/2Recently updatedNCT05919264

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Intervention: FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab, FOG-001

Sponsor: Parabilis Medicines, Inc.

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

Ages 18 Years+32 locations
Started May 2023Updated 3 weeks agoEst. Apr 2027 (~4 months)
RecruitingTreatment trialPhase 2Recently updatedNCT05949099

Study of Cryoablation and Nirogacestat for Desmoid Tumor

Intervention: Nirogacestat, Cryoablation

Sponsor: Nam Bui · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

The primary purpose of this protocol is Systemic therapy with oral study agent, nirogacestat, followed by a single cryoablation procedure.

Ages 18 Years+1 location
Started Aug 2023Updated 1 month agoEst. Feb 2028 (~1y 3m)
RecruitingObservational study, no treatment givenRecently updatedNCT02402244

Project: Every Child for Younger Patients With Cancer

Intervention: Cytology Specimen Collection Procedure, Medical Chart Review

Sponsor: Children's Oncology Group

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Ages up to 25 Years279 locations
Started Nov 2015Updated 2 months agoEst. Dec 2030 (~4y 1m)
Find Desmoid Tumors trials near you, ranked by distance →
Active trial locations183 cities in the US
+175 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Phase 4
Observational
Observational
RecruitingOpening soonDelayed startTodayHover a bar for trial details

Read more about Desmoid Tumors trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Desmoid Tumors foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Desmoid Tumors patient communities

Facebook groups, Reddit communities and YouTube channels where Desmoid Tumors patients, caregivers and advocacy groups talk.

Companies developing Desmoid Tumors treatments

Drugmakers that list Desmoid Tumors in their rare disease portfolio, 1 in all.

Questions people ask about Desmoid Tumors